At the National Comprehensive Cancer Network (NCCN) 21st Annual Conference, Alan P. Venook, MD, professor of Clinical Medicine at the University of California, San Francisco, provided insight into lessons learned by oncologists in the treatment of colorectal cancer.
Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.
Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.
At the National Comprehensive Cancer Network (NCCN)'s 21st Annual Conference, Robert Carlson, MD, chief executive officer, NCCN, provided a flavor for their value framework, the Evidence Blocks.
At the National Comprehensive Cancer Network 21st Annual Conference, John A. Thompson, MD, presented an update on where the field of melanoma treatment stands today.
Palliative care should be introduced as early as possible, even as early as diagnosis, so patients hear about it early and not during a late stage of their disease when they might need hospice, Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing, said at the National Comprehensive Cancer Network Annual Meeting.
High-quality cancer care must include palliative care in addition to the more traditional care, such as oncology, radiology, surgery, and imaging, Toby C. Campbell, MD, MSCI, associate professor of medicine, hematology-oncology at the University of Wisconsin School of Medicine and Public Health and chief of Palliative Care and program director of the Hospice and Palliative Medicine Fellowship Training Program, said at the National Comprehensive Cancer Network Annual Conference.
During the opening session at the National Comprehensive Cancer Network 21st Annual Conference, healthcare providers came together to discuss palliation from the provider and the patient perspective.
Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.
Despite the fact that warfarin is more easily reversible, bleeding complications with the therapy are associated with longer stays in the hospital and higher mortality than dabigatran and rivaroxaban.
Research on the post-marketing surveillance of rivaroxaban found that the drug was as safe as determined from the results of the anticoagulant’s randomized controlled trial.
Patients with atrial fibrillation and renal disease who were treated with rivaroxaban (Xarelto) had less of a risk of fatal bleeding, according to a study presented at the American Heart Association Scientific Session.
Physicians are sticking with what they know when it comes to prescribing treatment for deep vein thrombosis and pulmonary embolism. Researchers found that the most common treatment remains parenteral anticoagulant with warfarin despite the arrival of a the new treatment option rivaroxaban.
Using rivaroxaban in a patients with non-valvular atrial fibrillation can reduce rates of stroke and major bleeding, according to the result of the XANTUS study.
Primary clinical reviewers from the FDA and 2 clinician experts provided their unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma: daratumumab (Darzalex), ixazomib (Ninlaro), and elotuzumab (Empliciti).
Results from a subgroup analysis of the phase 3 ENDEAVOR study and a phase 2 study in diffuse large B cell lymphoma patients were presented at the annual meeting of the American Society of Hematology.
Members from the American Society of Hematology (ASH)'s Choosing Wisely Task Force presented 5 recommendations on Monday, December 7, 2015, at the 57th annual meeting of ASH, in Orlando, Florida.
On the second day of the annual meeting of the American Society of Hematology, physicians got together to discuss the real-world needs of alternate payment models in hematology.
During a health outcomes session on the second day of the American Society of Hematology meeting, data presented from a study conducted at the University of Nebraska Medical Center suggested that the site of care bears a significant influence on the outcomes of patients with acute lymphoblastic leukemia.
Two posters presented at the annual meeting of the American Society of Hematology discussed patient-reported outcomes measures and quality-of-life indicators as supportive tools for treatment in individuals being treated for acute myeloid leukemia and myelodysplastic syndrome.
Presenters at an education session, titled Patient-Reported Outcomes in Hematology, addressed the importance of embracing the patient perspective in healthcare delivery, on the second day of the annual meeting of the American Society of Hematology, being held December 5-8, in Orlando, Florida.
At the annual meeting of the American Society of Hematology, providers brooded over implications of quality measures and how they will influence clinical practice in the coming years.
An early session on the first day of the annual meeting and exposition of the American Society of Hematology, being held December 5-8, 2015, in Orlando, Florida, saw presentations on the promise of newly approved hematology/oncology agents, in addition to the challenges that clinicians face in treating patients with these drugs.
In a session at the Fall Managed Care Forum 2015, in Las Vegas, Nevada, cardiology expert Harold Bays MD, FTOS, FACC, FACE, FNLA, emphasized the importance of greater adherence to evidence-based practice guidelines, and the relevance of treatment with omega-3 fatty acids in hypertriglyceridemia.
Pulmonary arterial hypertension (PAH) is characterized by nonspecific symptoms, which can lead to a delay in diagnosis. Without treatment, patients with PAH have a poor prognosis, but development and availability of PAH-specific therapies have improved the overall prognosis of the disease.
The Medicare Shared Savings Program is the perfect way for primary care physicians to get involved with alternative payments as Medicare moves to replace fee-for-service, explained Hymin Zucker, MD, chief medical officer of the Triple Aim Development Group.
Panelist discuss early referral to palliative care, enduring misconceptions, culture considerations, and more at the Fall Managed Care Forum 2015.
A look at effective anticoagulation strategies for stroke prevention in patients with atrial fibrillation.
There is an enormous medication adherence problem in the United States, and millions of people could benefit from cognitive therapy, and technology can help.
As the healthcare industry positions itself for the change to value-based care, there needs to be a widespread change in terms of collaboration between physicians, hospitals, and payers.